These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23487220)

  • 1. Tetrabenazine and suicidal ideation.
    Shahani L
    J Neuropsychiatry Clin Neurosci; 2013; 25(1):E30. PubMed ID: 23487220
    [No Abstract]   [Full Text] [Related]  

  • 2. Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study.
    Dorsey ER; Brocht AF; Nichols PE; Darwin KC; Anderson KE; Beck CA; Singh S; Biglan KM; Shoulson I
    J Huntingtons Dis; 2013; 2(4):509-15. PubMed ID: 25062735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrabenazine, depression and suicide: good news.
    Margolis RL
    J Huntingtons Dis; 2014; 3(2):137-8. PubMed ID: 25062856
    [No Abstract]   [Full Text] [Related]  

  • 4. Tardive Syndrome Associated With Tetrabenazine in Huntington Disease: A Case Report.
    Palermo G; Mazzucchi S; Unti E; Bonuccelli U; Ceravolo R
    J Clin Psychopharmacol; 2020; 40(6):628-630. PubMed ID: 33136925
    [No Abstract]   [Full Text] [Related]  

  • 5. [Tetrabenazine (tetrabenazine Orphan) orally].
    J Pharm Belg; 2014 Dec; (4):49-50. PubMed ID: 25562927
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluating depression and suicidality in tetrabenazine users with Huntington disease.
    Schultz JL; Killoran A; Nopoulos PC; Chabal CC; Moser DJ; Kamholz JA
    Neurology; 2018 Jul; 91(3):e202-e207. PubMed ID: 29925548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetrabenazine (Xenazine) for Huntington's chorea.
    Med Lett Drugs Ther; 2009 Jan; 51(1304):7-8. PubMed ID: 19172140
    [No Abstract]   [Full Text] [Related]  

  • 8. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
    Guay DR
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):331-73. PubMed ID: 20869622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):65-68. PubMed ID: 29667946
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.
    Nozaki I; Furukawa Y; Kato-Motozaki Y; Ikeda T; Tagami A; Takahashi K; Ishida C; Komai K
    Intern Med; 2014; 53(11):1201-4. PubMed ID: 24881749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological properties and clinical efficacy of tetrabenazine (Choreazine(®)Tablets 12.5 mg), a therapeutic agent for non-rhythmic involuntary movement].
    Machida K; Kawakami D; Miki M
    Nihon Yakurigaku Zasshi; 2014 Mar; 143(3):144-51. PubMed ID: 24614638
    [No Abstract]   [Full Text] [Related]  

  • 12. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Jankovic J
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrabenazine for Huntington's chorea.
    Soutar CA
    Br Med J; 1970 Oct; 4(5726):55. PubMed ID: 4248502
    [No Abstract]   [Full Text] [Related]  

  • 14. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
    Dean M; Sung VW
    Drug Des Devel Ther; 2018; 12():313-319. PubMed ID: 29497277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
    Chen JJ; Ondo WG; Dashtipour K; Swope DM
    Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The suppression of involuntary movements with tetrabenazine.
    McLellan DL
    Scott Med J; 1972 Nov; 17(11):367-70. PubMed ID: 4264428
    [No Abstract]   [Full Text] [Related]  

  • 17. Tetrabenazine for the treatment of tardive dyskinesia.
    Leung JG; Breden EL
    Ann Pharmacother; 2011 Apr; 45(4):525-31. PubMed ID: 21487088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term effect of tetrabenazine in the management of Huntington disease.
    Fasano A; Cadeddu F; Guidubaldi A; Piano C; Soleti F; Zinzi P; Bentivoglio AR
    Clin Neuropharmacol; 2008; 31(6):313-8. PubMed ID: 19050408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for tolerability of tetrabenazine in patients with hyperkinetic movement disorders.
    Sahin T; Yilmaz R; Akbostanci MC
    Parkinsonism Relat Disord; 2020 May; 74():36-37. PubMed ID: 32311641
    [No Abstract]   [Full Text] [Related]  

  • 20. Tetrabenazine as a cause of neuroleptic malignant syndrome.
    Ossemann M; Sindic CJ; Laterre C
    Mov Disord; 1996 Jan; 11(1):95. PubMed ID: 8771075
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.